Skip to main content
2024 Guide to Patient Support Services

Pfizer Oncology

2024 PSS Guide

Pfizer Oncology Together

Pfizer offers Pfizer Oncology Together, a patient support program to help patients access their prescribed Pfizer Oncology medications, identify financial assistance options, and connect patients to a dedicated Care Champion. A complete list of Pfizer Oncology medications and their related assistance programs is provided in the Table.

Pfizer Oncology Together

Pfizer Oncology Together offers the Pfizer Oncology Together Co-Pay Savings Program, the Pfizer Patient Assistance Program, and the Care Champion Program.

Pfizer Oncology Together Co-Pay Savings Program

Co-pay savings are available for eligible, commercially insured patients who are prescribed certain Pfizer Oncology oral or injectable medications. Limits, terms, and conditions apply depending on the medication prescribed. To learn more or to enroll your patient in Pfizer Oncology Together Co-Pay Savings Program, please visit the Pfizer Oncology Together Co-Pay Savings Program or call 877-744-5675.

Pfizer Patient Assistance Program

Through the Pfizer Patient Assistance Program, uninsured patients may receive free medication for up to 1 calendar year, while underinsured patients are enrolled through the end of the calendar year. To be evaluated for assistance through this program, you and your patient must each submit a completed enrollment form. Patients must also provide proof of income, such as the prior year’s tax return, a W-2 form, or paycheck stub.

To learn more or to enroll your patient in the Pfizer Pa­tient Assistance Program, please visit www.pfizeroncologytogether.com/hcp/patient-financial-assistance#insurance-types or call 877-744-5675.

Care Champion Program

The Care Champion Program is a free patient support program for patients prescribed a Pfizer Oncology medication. Patients are partnered with a dedicated Care Champion who has social work experience and can provide resources that may help with some of their daily challenges, no matter where they are in the treatment journey. To learn more or to enroll your patient in the Care Champion Program, please visit www.pfizeroncologytogether.com/hcp/patient-support#care-champion-­program.

Free Trial Vouchers

Patients who have been newly prescribed certain Pfizer Oncology medications may be able to start therapy with a free trial voucher. To learn more or to find out which medications offer trial vouchers, visit www.pfizeroncologytogether.com/hcp/patient-financial-assistance#free-trial-­vouchers or see Table.

TABLE Pfizer Oncology/Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Aromasin (exemestane) tablets
Indications
Adjuvant treatment of postmenopausal women with estrogen receptor–positive early breast cancer who have received 2 to 3 years of tamoxifen and are switched to Aromasin for completion of 5 consecutive years total of adjuvant hormonal therapy; treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy
Patient support programs

Drug
Besponsa (inotuzumab ozogamicin)
Indications
Treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Patient support programs

Drug
Bosulif (bosutinib)
Indications
Treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome–positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy; adult patients with accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy
Patient support programs

Drug
Braftovi (encorafenib)
Indications
Treatment, in combination with binimetinib, of patients with unresectable or metastatic melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test; treatment, in combination with cetuximab, of adults with metastatic colorectal cancer and a BRAF V600E mutation, as detected by an FDA-approved test, after previous therapy; treatment, in combination with binimetinib, of adult patients with metastatic non–small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved test
Patient support programs

Drug
Camptosar (irinotecan hydrochloride) injection
Indications
First-line therapy, in combination with 5-fluorouracil and leucovorin, for patients with metastatic carcinoma of the colon or rectum; treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy
Patient support programs

Drug
Daurismo (glasdegib)
Indications
In combination with low-dose cytarabine, treatment of newly diagnosed acute myeloid leukemia in adults aged ≥75 years or patients whose comorbidities preclude intensive chemotherapy induction
Patient support programs

Drug
Ellence (epirubicin hydrochloride) injection
Indications
A component of adjuvant therapy in patients with breast cancer with evidence of axillary node tumor involvement after primary resection
Patient support programs

Drug
Elrexfio (elranatamab-bcmm)
Indications
Treatment of adults with relapsed/refractory multiple myeloma who received ≥4 lines of previous therapy, including proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody
Patient support programs

Drug
Emcyt (estramustine phosphate sodium)
Indications
Palliative treatment of patients with metastatic and/or progressive prostate cancer
Patient support programs

Drug
Ibrance (palbociclib)
Indications
Treatment of adult patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer in combination with either an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients with disease progression following endocrine therapy
Patient support programs

Drug
Idamycin PFS (idarubicin hydrochloride)
Indications
Treatment of acute myeloid leukemia in adults, with other antileukemic drugs
Patient support programs

Drug
Inlyta (axitinib)
Indications
In combination with avelumab, for the first-line treatment of advanced renal cell carcinoma (RCC); in combination with pembrolizumab, for the first-line treatment of advanced RCC; as a single agent, for the treatment of advanced RCC after failure of 1 prior systemic therapy
Patient support programs

Drug
Lorbrena (lorlatinib)
Indications
Treatment of metastatic non–small cell lung cancer with ALK mutation, as determined by an FDA-approved test
Patient support programs

Drug
Mektovi (binimetinib)
Indications
Treatment, in combination with encorafenib, of patients with unresectable or metastatic melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test; treatment, in combination with encorafenib, of adult patients with metastatic non–small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved testt
Patient support programs

Drug
Mylotarg (gemtuzumab ozogamicin)
Indications
Treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older; treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older
Patient support programs

Drug
Nivestym (filgrastim-aafi) injection
Indications
Patient support programs

Drug
Nyvepria (pegfilgrastim-apgf)
Indications
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia
Patient support programs

Drug
Retacrit (epoetin alfa-epbx)
Indications
Treatment of anemia associated with concomitant myelosuppressive chemotherapy
Patient support programs

Drug
Ruxience (rituximab-pvvr)
Indications
Patient support programs

Drug
Sutent (sunitinib malate)
Indications
Treatment of adult patients with gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate; treatment of adult patients with advanced renal cell carcinoma (RCC); adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy; treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in adult patients with unresectable locally advanced or metastatic disease
Patient support programs

Drug
Talzenna (talazoparib)
Indications
As a single-agent treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative, locally advanced or metastatic breast cancer, based on an FDA-approved companion diagnostic; in combination with enzalutamide for the treatment of adult patients with HRR-mutated, metastatic castration-resistant prostate cancer
Patient support programs

Drug
Torisel (temsirolimus)
Indications
Treatment of advanced renal cell carcinoma
Patient support programs

Drug
Trazimera (trastuzumab-qyyp)
Indications
Treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients for therapy based on an FDA-approved companion diagnostic
Patient support programs

Drug
Vizimpro (dacomitinib)
Indications
First-line treatment of metastatic non–small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test
Patient support programs

Drug
Xalkori (crizotinib)
Indications
Treatment of patients with metastatic non–small cell lung cancer whose tumors are ALK- or ROS1-positive, as detected by an FDA-approved test; pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large-cell lymphoma that is ALK-positive; adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor that is ALK-positive
Patient support programs

Drug
Zirabev (bevacizumab-bvzr)
Indications
First- or second-line treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy; second-line treatment of metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line bevacizumab regimen
Patient support programs

Nivestym (filgrastim-aafi) injection Indications

To decrease the incidence of infection (as manifested by febrile neutropenia) in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever; reduce time to neutrophil recovery and duration of fever after chemotherapy in patients with acute myeloid leukemia; to reduce duration of neutropenia and neutropenia-related sequelae in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplant; for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis; to reduce incidence/duration of severe neutropenia sequelae in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia

Ruxience (rituximab-pvvr) injection Indications

Treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; nonprogressing, low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy; previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone, or other anthracycline-based chemotherapy regimens; in combination with fludarabine and cyclophosphamide, for the treatment of adult patients with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia